<u>Materials Design Analysis Reporting (MDAR)</u> Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

Report on age and sex for all study participants.

Materials

Antibodies	Yes (indicate where provided: section/paragraph)	n/a
For commercial reagents, provide supplier		No antibodies
name, catalogue number and RRID, if available.		were used
Cell materials	Yes (indicate where provided: section/paragraph)	n/a
Cell lines: Provide species information, strain.		No cell lines
Provide accession number in repository OR		were used
supplier name, catalog number, clone number, OR RRID		
Primary cultures: Provide species, strain, sex of		No cell lines
origin, genetic modification status.		were used
Experimental animals	Yes (indicate where provided: section/paragraph)	n/a
Laboratory animals: Provide species, strain, sex, age,		No animal
genetic modification status. Provide accession		experiments
number in repository OR supplier name, catalog		were done
number, clone number, OR RRID		
Animal observed in or captured from the		No animal
field: Provide species, sex and age where		experiments
possible		were done
Model organisms: Provide Accession number		No animal
in repository (where relevant) OR RRID		experiments
Plants and microbes	Yes (indicate where provided: section/paragraph)	n/a
Plants: provide species and strain, unique accession		No plant
number if available, and source (including location		experiments
for collected wild specimens)		were done
Microbes: provide species and strain, unique		No microbial
accession number if available, and source		experiments
		were done
Human research participants	Yes (indicate where provided: section/paragraph)	n/a
Identify authority granting ethics approval (IRB or		Not human
equivalent committee(s), provide reference number		research
for approval.		participants
Provide statement confirming informed consent		Not study
obtained from study participants.		participants
on tame and the state of participants.		

Age and sex are not the contents of this study

Design

Study protocol	Yes (indicate where provided: section/paragraph)	n/a
For clinical trials, provide the trial registration		Not a clinical
number OR cite DOI in manuscript.		trial
Laboratory protocol	Yes (indicate where provided: section/paragraph)	n/a
Provide DOI or other citation details if detailed step-		No citation for
by-step protocols are available.		detailed
		protocols
Experimental study design (statistics details)	Yes (indicate where provided: section/paragraph)	n/a
State whether and how the following have been	, , , , , , , , , , , , , , , , , , , ,	·
done, or if they were not carried out.		
Sample size determination	Yes (Collection of datasets /paragraph 1)	
Randomisation	Yes (Collection of datasets /paragraph 1)	
Blinding	Yes (Collection of datasets /paragraph 1)	
Inclusion/exclusion criteria	Yes (Collection of datasets /paragraph 1)	
Sample definition and in-laboratory replication	Yes (indicate where provided: section/paragraph)	n/a
State number of times the experiment was		No experimer
replicated in laboratory		in laboratory
		was done
Define whether data describe technical or biological		No experimer
replicates		in laboratory
·		was done
Ethics	Yes (indicate where provided: section/paragraph)	n/a
Studies involving human participants: State details of	, and the second process of the second proce	Not human
authority granting ethics approval (IRB or equivalent		research
committee(s), provide reference number for		participants
approval.		
Studies involving experimental animals: State details		No animal
of authority granting ethics approval (IRB or		experiments
equivalent committee(s), provide reference number		were done
for approval.		
Studies involving specimen and field samples: State if		Not specimer
relevant permits obtained, provide details of		and field
authority approving study; if none were required,		sample
explain why.		
Dual Use Research of Concern (DURC)	Yes (indicate where provided: section/paragraph)	n/a
If study is subject to dual use research of concern,		Not dual use
state the authority granting approval and reference		research
number for the regulatory approval	I	

Analysis

Attrition	Yes (indicate where provided: section/paragraph)	n/a
State if sample or data point from the analysis is excluded, and whether the criteria for exclusion were determined and specified in advance.	Yes (Collection of datasets /paragraph 1)	

Statistics	Yes (indicate where provided: section/paragraph)	n/a
Describe statistical tests used and justify choice of	Yes (Statistical analysis section/paragraph 1)	
tests.		

Data Availability	Yes (indicate where provided: section/paragraph)	n/a
State whether newly created datasets are available,	Yes (Collection of datasets /paragraph 1)	
including protocols for access or restriction on		
access.		
If data are publicly available, provide accession	Yes (Collection of datasets /paragraph 1)	
number in repository or DOI or URL.		
If publicly available data are reused, provide	Yes (Collection of datasets /paragraph 1)	
accession number in repository or DOI or URL, where		
possible.		

Code Availability	Yes (indicate where provided: section/paragraph)	n/a
For all newly generated code and software essential		
for replicating the main findings of the study:		
State whether the code or software is available.	Yes (Methods /paragraph 2, 3 and 4)	
If code is publicly available, provide accession	Yes (Methods /paragraph 2, 3 and 4)	
number in repository, or DOI or URL.		

Reporting

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of		
discipline-specific guidelines, established and		
endorsed through community initiatives. Journals		
have their own policy about requiring specific		
guidelines and recommendations to complement		
MDAR.		
State if relevant guidelines (eg., ICMJE, MIBBI,	ICMJE guidelines were followed, as the journal follows	
ARRIVE) have been followed, and whether a checklist	ICMJE recommendations for publication.	
(eg., CONSORT, PRISMA, ARRIVE) is provided with		
the manuscript.		

Article information: http://dx.doi.org/10.21037/atm-20-7759